1. Gilead may be looking to buy oncology startup Forty-Seven —FDA announces that COVID-19 has caused its first US drug shortage — Passage Bio raises upsized $216M IPO — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice
Latest trending news Ask a Whistleblower Attorney forum

B Field

Discussion in 'NuVasive' started by anonymous, Mar 4, 2018 at 7:01 PM.

  1. #1 anonymous, Mar 4, 2018 at 7:01 PM
    anonymous

    anonymous Guest

    Brian F is the worst and easily the most annoying manager I have ever worked with. He sucked as a Synthes rep which by the way I have personally herd him tell Docs that he was one for 7 years and 10 years and then he bounced out of Medtronic after a year.

    Nuvasive and their Corp management are clueless about Precice.

    This company will be in flux for years to come, way to go Nuvasive for taking an amazing company to work for and trash it.
     
    Quote
  2. #2 anonymous, May 23, 2018 at 11:15 PM
    anonymous

    anonymous Guest

    B Field is an ass kisser and is jammed up Balkman’s backside. Dude talks like he has had a great run in trauma in the past and then you talk to those in Synthes that know that he really wasn’t worth anything.

    Terrible leadership from a NuVasive. No surprise.
     
    Quote
Reply to Thread